enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pertuzumab/trastuzumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab/trastuzumab/...

   The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...

3. Breast cancer management - Wikipedia

   en.wikipedia.org/wiki/Breast_cancer_management

   Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.

4. Trastuzumab/hyaluronidase - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab/hyaluronidase

   Combination of; Trastuzumab: HER2/neu receptor antagonist: ... is a fixed-dose combination medication for the treatment of HER2-overexpressing breast cancer in adults

5. Pertuzumab - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab

   Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...

6. Trastuzumab - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab

   The safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer. [clarification needed] The overall hazard ratios (HR) for overall survival and progression free survival were 0.82 and 0.61, respectively.

7. Chemotherapy regimen - Wikipedia

   en.wikipedia.org/wiki/Chemotherapy_regimen

   The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas. The term " induction regimen " refers to a chemotherapy regimen used for the initial treatment of a disease. A " maintenance regimen " refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer ...

8. Dying To Be Free - The Huffington Post

   projects.huffingtonpost.com/dying-to-be-free...

   What addicts face is a revolving door, an ongoing cycle of waiting for treatment, getting treatment, dropping out, relapsing and then waiting and returning for more. Like so many others, Tabatha Roland, the 24-year-old addict from Burlington, wanted to get sober but felt she had hit a wall with treatment.

9. Trastuzumab deruxtecan - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab_deruxtecan

   Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...